Who are oral contraceptive pills's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OC - Drospirenone plus Ethynylestradiol, Add back therapy 1 (tibolone), EE20/DRSP (YAZ, BAY86-5300), oral contraceptives, Microgestin®, ethinyl estradiol and cyproterone acetate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-contraceptive-pills.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

oral contraceptive pills — Competitive Intelligence Brief

oral contraceptive pills (oral contraceptive pills) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormonal contraceptive. Area: Contraception / Reproductive Health.

marketed Hormonal contraceptive Estrogen receptor, Progesterone receptor Contraception / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

oral contraceptive pills (oral contraceptive pills) — Kayseri Education and Research Hospital. Oral contraceptive pills prevent pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-gonadal axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
oral contraceptive pills TARGET	oral contraceptive pills	Kayseri Education and Research Hospital	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
OC - Drospirenone plus Ethynylestradiol	OC - Drospirenone plus Ethynylestradiol	Federico II University	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor, mineralocorticoid receptor
Add back therapy 1 (tibolone)	Add back therapy 1 (tibolone)	University of Cagliari	marketed	Selective Tissue Estrogenic Activity Regulator (STEAR); Hormone Replacement Therapy	Estrogen receptor, Progesterone receptor, Androgen receptor
EE20/DRSP (YAZ, BAY86-5300)	EE20/DRSP (YAZ, BAY86-5300)	Bayer	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen receptor, progesterone receptor, mineralocorticoid receptor
oral contraceptives	oral contraceptives	FHI 360	marketed	Hormonal contraceptive	Estrogen receptor, Progesterone receptor
Microgestin®	Microgestin®	Ironwood Pharmaceuticals, Inc.	marketed	Oral contraceptive (combined estrogen-progestin)	Estrogen receptor, progesterone receptor
ethinyl estradiol and cyproterone acetate	ethinyl estradiol and cyproterone acetate	S.C.B. Medical College and Hospital	marketed	Combined oral contraceptive with anti-androgenic activity	Estrogen receptor, progesterone receptor, androgen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormonal contraceptive class)

Penn State University · 2 drugs in this class
Italfarmaco · 1 drug in this class
Kayseri Education and Research Hospital · 1 drug in this class
TherapeuticsMD · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
University of Athens · 1 drug in this class
FHI 360 · 1 drug in this class
University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oral contraceptive pills — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-contraceptive-pills. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab